Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
NCT07314203 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 118
Last updated 2026-01-02
Summary
Exploring the pathological complete response rate (pCR) of locally advanced gastric cancer treated with adebelimab combined or not combined with apatinib mesylate and SOX neoadjuvant therapy
Conditions
- Gastric Cancer
- Surgery
Interventions
- DRUG
-
Apatinib Mesylate Tablets
Apatinib Mesylate
Sponsors & Collaborators
-
Fujian Medical University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-12-25
- Primary Completion
- 2027-08-25
- Completion
- 2028-08-25
Countries
- China
Study Locations
More Related Trials
-
Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
NCT06475417 ·Status: RECRUITING ·Phase: PHASE2
-
Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma
NCT06192186 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06415669 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
NCT04338438 ·Status: COMPLETED ·Phase: PHASE2
-
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
NCT07026149 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
NCT06776770 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06925243 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
NCT05524974 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
NCT03229096 ·Status: UNKNOWN ·Phase: PHASE2
-
Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer
NCT04792515 ·Status: UNKNOWN ·Phase: PHASE2
-
The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer
NCT03007446 ·Status: UNKNOWN ·Phase: PHASE2
-
Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.
NCT03144843 ·Status: UNKNOWN ·Phase: PHASE2
-
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
NCT06684158 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
NCT06194981 ·Status: RECRUITING
-
Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ
NCT06808971 ·Status: RECRUITING ·Phase: PHASE2
-
Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05024812 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients
NCT02338518 ·Status: UNKNOWN ·Phase: PHASE3
-
Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
NCT06985602 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
NCT07023315 ·Status: RECRUITING ·Phase: PHASE3
-
A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
NCT06339216 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer
NCT07132528 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
NCT03702491 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
NCT07149181 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
NCT02697838 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of the Apatinib Combine With POF Versus POF in Gastric Cancer
NCT04121039 ·Status: UNKNOWN ·Phase: PHASE2